Skip to main content
. 2018 Apr 9;5(1):57–73. doi: 10.1007/s40744-018-0108-4

Table 2.

Base case results

Treatment Total costs (£) Total QALYs Incremental costs (£) Incremental QALYs ICER (£)
Conventional therapy (reference) 107,138 6.93
Golimumab 146,908 9.00 39,770 2.06 19,280
Adalimumab 148,247 9.02 41,110 2.08 19,737
Certolizumab pegol 154,233 9.45 47,095 2.52 18,710
Etanercept 142,933 8.72 35,795 1.78 20,089

ICER Incremental cost-effectiveness ratio, QALY Quality-adjusted life-year